FindMyKOL
Clinical trialNCT07432880RecruitingObservational

A Prospective Study of Pediatric Participants up to 16 Years of Age With Methylmalonic Acidemia (MMA) Due to Mutations in the MMUT Gene

SponsorGenespire SrlEnrollment30Methylmalonic Acidemia (MMA)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Methylmalonic Acidemia (MMA) is a severe and rare condition that affects how the body turns food into energy. In people with MMA, the body is missing or has a very low activity of a specific protein (an enzyme called methylmalonyl-CoA mutase (MMUT)) needed to break down certain proteins and fats in everyday food. Because this process does not work properly, a harmful substance called methylmalonic acid builds up in the blood and tissues, causing damage in the body. Most people with MMA have an altered MMUT gene, which affects the enzyme methylmalonyl-CoA mutase. MMA often appears in infancy or early childhood, but some people are diagnosed later. MMA affects approximately 1 in every 100,000 babies born and primarily impacts the liver, brain and kidneys. MMA poses significant challenges as it can result in complications such as dangerous acid levels in the blood, problems with the brain and nerves, visions problems, problems with how the pancreas, liver, and the kidneys work, as well as growth and development delays. The main purpose of this observational study that tracks how the disease develops over time is to gather necessary data and evidence to confirm which signs in the body and blood test results can reliably show disease activity related to MMA. These confirmed signs and blood test results will be used for future research into developing new treatments for MMA. The data will be collected from participants with severe symptoms with and without liver transplant.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Italy
  • Osr_san Raffaele

    Milan, Italy

    Migliavacca, PhD
    Not, yet, recruiting
  • Obgp (bambino Gesu Ospedale Pediatrico)

    Roma, Italy

    Martinelli, PhD
    Not, yet, recruiting
Spain
  • Sjd_san Joan de deù Children'S Hospital

    Barcelona, Spain

    García Cazorla, PhD
    Recruiting
  • Hospital Universitario 12 de Octubre

    Madrid, Spain

    Bellusci, PhD
    Not, yet, recruiting
United Kingdom
  • Gosh Nhs (great Ormond Street Hospital for Children)

    London, United Kingdom

    Anupam, PhD
    Recruiting
  • Saint Mary'S Hospital

    Manchester, United Kingdom

    Schwahn, PhD
    Recruiting
United States
  • Chop (children'S Hospital of Philadelphia)

    Philadelphia, Pennsylvania, United States

    can Ficicioglu, PhD
    Recruiting
  • Upmc (children'S Hospital of Pittsburgh)

    Pittsburgh, Pennsylvania, United States

    Gerard Vockley, PhD
    Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
13 Aug 2026
Primary completion
31 Aug 2030
Completion
31 Aug 2030
Last update posted
16 Nov 2026
Registered enrollment
30
Registry id
NCT07432880

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.